High Risk
17
3
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
29%
5 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (17)
Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia
Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas
Remote Cardiotocography Telemonitoring Within High-risk Pregnancy Care
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
General Decolonization With Octenisan® Set Before Elective Orthopedic Surgery
68 Ga-PSMA for High Risk Prostate Cancer
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
Tauropace to Prevent Cardiac Implantable Device Infections in Heart Failure Patients
Designing a Personalized Diet to Reduce the Risk of Crohn's Disease Onset
Imaging vs. no Testing in Asymptomatic High-risk Diabetic Patients
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients